- 1Division of Thoracic Surgery, Saitama Cancer Center, Saitama, Hidaka, Japan.
- 2Division of Thoracic Oncology, Saitama Cancer Center, Saitama, Hidaka, Japan.
- 3Department of Pathology, Saitama Cancer Center, Saitama, Hidaka, Japan.
- 4Department of Radiation Oncology, Saitama Cancer Center, Saitama, Hidaka, Japan.
- 5Department of Respiratory Medicine, Saitama International Medical Center, Hidaka, Japan.
Abstract
BACKGROUND:
Although the concept of induction therapy followed by surgical resection for locally advanced non-small cell lung cancer (LA-NSCLC) has found general acceptance, the appropriate indications and the strategy for this treatment are still controversial.
METHODS:
From 2000 through 2008, 36 patients received concurrent chemoradiotherapy followed by surgery. We retrospectively reviewed these cases, analyzed the outcomes and examined the prognosis.
RESULTS:
The median radiation dose given was 60 Gy. Chemotherapy included a platinum agent in all cases; cisplatin-based chemotherapy was administered to 9 cases, and a carboplatin-based chemotherapy regimen was administered to 27. A complete resection was performed in 94% of the patients. Seventeen (47.2%) patients exhibited a complete pathological response, and downstaging was induced in 26 (72%) cases. The morbidity and 30-day mortality rates were 11.1 and 0%, respectively. The 5-year overall survival rate in the patients with complete resection (n = 33) was 83.3%.
CONCLUSIONS:
Induction chemoradiotherapy followed by surgery for LA-NSCLC provided a favorable prognosis for selected patients. A complete pathological response was found in about half of cases. This strategy is feasible and was associated with low morbidity and high resectability rates, suggesting that it contributed to improving the treatment results.
No comments:
Post a Comment